Latest Breaking News On - Liraglutide sublingual - Page 1 : comparemela.com

BioLingus (Cayman) Ltd (SUBL) Plans to Raise $7 Million in January 31st IPO

BioLingus (Cayman) Ltd (SUBL) Plans to Raise $7 Million in January 31st IPO
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalCayman islandsUniversity of hong kongHong kong generalHong kongBiolingus cayman ltdNews ratings for biolingus cayman ltd dailyBiolingus platformLiraglutide sublingualClinical trials centreChinese universityLtd daily

BioLingus Limited Readies $47 Million IPO Plan (Pending:SUBL)

BioLingus is developing Liraglutide, a drug treatment for diabetes patients. Click here to see our take on SUBL.

Hong kongCayman islandsEnteris biopharmaStragen pharmaYves decadtMedimetricsa philipsCompany pipelineVp business development at skyepharmaBiolingus caymanNovo nordiskOramed pharmaceuticalsBiolingus cayman limitedBiolingus cayman limited financial statusGiven biolingus caymanA quick take on biolingus caymanQuick take on biolingus